MX2018012508A - Combinaciones para el tratamiento de neoplasias utilizando localizacion de celulas quiescentes e inhibidores de la mitosis. - Google Patents
Combinaciones para el tratamiento de neoplasias utilizando localizacion de celulas quiescentes e inhibidores de la mitosis.Info
- Publication number
- MX2018012508A MX2018012508A MX2018012508A MX2018012508A MX2018012508A MX 2018012508 A MX2018012508 A MX 2018012508A MX 2018012508 A MX2018012508 A MX 2018012508A MX 2018012508 A MX2018012508 A MX 2018012508A MX 2018012508 A MX2018012508 A MX 2018012508A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- mitosis
- neoplasms
- inhibitors
- combinations
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000011278 mitosis Effects 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 229940121849 Mitotic inhibitor Drugs 0.000 abstract 1
- 238000011394 anticancer treatment Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323583P | 2016-04-15 | 2016-04-15 | |
| PCT/US2017/027734 WO2017181087A1 (en) | 2016-04-15 | 2017-04-14 | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018012508A true MX2018012508A (es) | 2019-07-08 |
Family
ID=60039311
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012508A MX2018012508A (es) | 2016-04-15 | 2017-04-14 | Combinaciones para el tratamiento de neoplasias utilizando localizacion de celulas quiescentes e inhibidores de la mitosis. |
| MX2022012146A MX2022012146A (es) | 2016-04-15 | 2018-10-12 | Combinaciones para el tratamiento de neoplasias utilizando localizacion de celulas quiescentes e inhibidores de la mitosis. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012146A MX2022012146A (es) | 2016-04-15 | 2018-10-12 | Combinaciones para el tratamiento de neoplasias utilizando localizacion de celulas quiescentes e inhibidores de la mitosis. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10314843B2 (enExample) |
| EP (1) | EP3443351A4 (enExample) |
| JP (1) | JP7278776B2 (enExample) |
| KR (2) | KR102494172B1 (enExample) |
| CN (1) | CN109313197A (enExample) |
| AU (2) | AU2017248807A1 (enExample) |
| BR (1) | BR112018071023A2 (enExample) |
| CA (1) | CA3020978A1 (enExample) |
| IL (2) | IL292475A (enExample) |
| MX (2) | MX2018012508A (enExample) |
| WO (1) | WO2017181087A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10322128B2 (en) | 2016-04-15 | 2019-06-18 | Felicitex Therapeutics, Inc. | Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2475368B1 (en) * | 2009-09-11 | 2014-12-17 | Amgen, Inc | N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer |
| US20120184562A1 (en) | 2011-01-19 | 2012-07-19 | Kin-Chun Luk | 1,6- and 1,8-naphthyridines |
| US9446044B2 (en) * | 2011-08-19 | 2016-09-20 | Diaxonhit | DYRK1 inhibitors and uses thereof |
| FR2993317B1 (fr) | 2012-07-16 | 2014-08-15 | Snecma | Carter de turbomachine dans un materiau composite et procede de fabrication associe |
| RU2016117729A (ru) * | 2012-10-10 | 2017-11-10 | Фелиситекс Терапеутикс, Инк. | Терапия рака путем таргетинга покоящихся раковых клеток |
| EA201600003A1 (ru) * | 2013-06-11 | 2016-06-30 | Байер Фарма Акциенгезельшафт | КОМБИНАЦИИ ДЛЯ ЛЕЧЕНИЯ РАКА, СОДЕРЖАЩИЕ ИНГИБИТОР Mps-1 КИНАЗЫ И ИНГИБИТОР МИТОЗА |
| CA2854542A1 (en) * | 2013-06-18 | 2014-12-18 | 4Sc Discovery Gmbh | Method of inhibiting dyrk1b |
| US9566280B2 (en) * | 2014-01-28 | 2017-02-14 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
| MA39763A (fr) | 2014-03-20 | 2017-01-25 | Samumed Llc | Indazole-3-carboxamides 5-substitués, et préparation et utilisation de ceux-ci |
| US20170304313A1 (en) | 2014-10-06 | 2017-10-26 | Novartis Ag | Therapeutic Combination For The Treatment Of Cancer |
| CN108135871B (zh) * | 2015-07-23 | 2022-11-04 | 博蔚医药生物科技股份有限公司 | 阻断疾病的泛素化-蛋白酶体系统的胺萘醌化合物及医药组合物 |
| US10322128B2 (en) | 2016-04-15 | 2019-06-18 | Felicitex Therapeutics, Inc. | Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors |
-
2017
- 2017-04-14 CN CN201780037724.5A patent/CN109313197A/zh active Pending
- 2017-04-14 US US15/488,143 patent/US10314843B2/en active Active
- 2017-04-14 CA CA3020978A patent/CA3020978A1/en active Pending
- 2017-04-14 WO PCT/US2017/027734 patent/WO2017181087A1/en not_active Ceased
- 2017-04-14 IL IL292475A patent/IL292475A/en unknown
- 2017-04-14 BR BR112018071023A patent/BR112018071023A2/pt not_active Application Discontinuation
- 2017-04-14 EP EP17783296.1A patent/EP3443351A4/en not_active Withdrawn
- 2017-04-14 AU AU2017248807A patent/AU2017248807A1/en not_active Abandoned
- 2017-04-14 KR KR1020187033030A patent/KR102494172B1/ko active Active
- 2017-04-14 JP JP2018554360A patent/JP7278776B2/ja active Active
- 2017-04-14 MX MX2018012508A patent/MX2018012508A/es unknown
- 2017-04-14 KR KR1020237002817A patent/KR20230020560A/ko not_active Ceased
-
2018
- 2018-10-11 IL IL262325A patent/IL262325B/en unknown
- 2018-10-12 MX MX2022012146A patent/MX2022012146A/es unknown
-
2019
- 2019-06-10 US US16/436,305 patent/US20190290651A1/en not_active Abandoned
-
2021
- 2021-12-21 US US17/558,204 patent/US20220110941A1/en not_active Abandoned
-
2023
- 2023-08-08 AU AU2023214240A patent/AU2023214240A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230020560A (ko) | 2023-02-10 |
| KR20180130575A (ko) | 2018-12-07 |
| CA3020978A1 (en) | 2017-10-19 |
| EP3443351A1 (en) | 2019-02-20 |
| KR102494172B1 (ko) | 2023-02-02 |
| MX2022012146A (es) | 2022-10-21 |
| US20220110941A1 (en) | 2022-04-14 |
| IL262325A (en) | 2018-11-29 |
| IL262325B (en) | 2022-06-01 |
| BR112018071023A2 (pt) | 2019-02-05 |
| AU2017248807A1 (en) | 2018-10-25 |
| IL292475A (en) | 2022-06-01 |
| US10314843B2 (en) | 2019-06-11 |
| EP3443351A4 (en) | 2019-12-18 |
| US20190290651A1 (en) | 2019-09-26 |
| CN109313197A (zh) | 2019-02-05 |
| WO2017181087A1 (en) | 2017-10-19 |
| AU2023214240A1 (en) | 2023-08-24 |
| JP7278776B2 (ja) | 2023-05-22 |
| US20170296542A1 (en) | 2017-10-19 |
| JP2019511553A (ja) | 2019-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012146A (es) | Combinaciones para el tratamiento de neoplasias utilizando localizacion de celulas quiescentes e inhibidores de la mitosis. | |
| MX2023000549A (es) | Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr. | |
| PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
| PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| PH12019502379A1 (en) | Pd-1/pd-l1 inhibitors | |
| ZA201802966B (en) | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment | |
| PH12017502391A1 (en) | Compositions and methods for inhibiting arginase activity | |
| BR112018073328A2 (pt) | combinação, composição farmacêutica, kit, método para tratamento de câncer, método para a redução de um nível de células, método para reduzir o nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade | |
| PH12016501550B1 (en) | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer | |
| EP4233870A3 (en) | Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids | |
| MX2017010773A (es) | Inhibidores de muerte programada 1 (pd-19)/ligando de muerte progamada 1 (pd-l1) para el tratamiento de cancer. | |
| EA201691376A1 (ru) | Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака | |
| EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
| MX2016001901A (es) | Biomarcadores para tratamiento de trastornos neoplasicos usando terapias dirigidas con andrógeno. | |
| MX2015013177A (es) | Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki. | |
| MX394452B (es) | Inhibicion de la actividad de olig2. | |
| MX2019013862A (es) | Terapia de combinacion. | |
| EA201990567A1 (ru) | Комбинированная терапия с ингибиторами глутаминазы | |
| MX380835B (es) | Terapia de combinación pac-1. | |
| ZA201901367B (en) | Inhibition of olig2 activity | |
| MX2019001337A (es) | Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer. |